Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. METHODS: In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes. Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks. The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point). RESULTS: A total of 272 participants underwent randomization. At baseline, the mean body weight was 108.7 kg, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 37.9. At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group. At week 36, the mean change ranged from -9.4% to -14.7% with orforglipron and was -2.3% with placebo. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo. The use of orforglipron led to improvement in all prespecified weight-related and cardiometabolic measures. The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts. The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class. CONCLUSIONS: Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“Between 65% and 96% of participants taking orforglipron achieved an A1C level below 7.0% at 26 weeks.174”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [174]
In the citing paper
“In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to −14.7% compared to −2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [25]
In the citing paper
“At 36 weeks, the mean percentage change from baseline in body weight ranged from e9.4 (95% CI, e11.5 to e7.4) to e14.7 (95% CI, e16.5 to e12.8) with orforglipron and was e2.3 (95% CI, e4.3 to e0.4) with placebo (Wharton et al, 2023)”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
In the citing paper
“In a multicenter phase 2 trial, 272 participants (mean age, 54.2 years; mean BMI, 37.9 kg/m 2 ) were randomly assigned to 1 of 4 doses of oral orforglipron (12, 24, 36, or 45 mg) once daily or placebo, for 36 weeks (Wharton et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wharton et al, 2023
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Self-citationDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Self-citationLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Cited by
Items 401–500 of 509
Metabolic bariatric surgery and pregnancy: balancing maternal benefits with neonatal risks
Iannelli, A., & Carandina, S. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101280
“4 Moreover, delaying pregnancy for at least 12 – 18 months post-MBS remains crucial.”
Grzebyk, M., Tokarska, A., Arnista, A., Świątko, M., Sosnowski, P., Rybak, J., Waszczuk, A., Kołodziejczyk, A. M., & Gawrońska, K. (2025) · Medical Science · doi:10.54905/disssi.v29i157.e50ms3543
Modder, M., Tomás, A., Afkir, S., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., van Eenige, R., Rensen, P. C. N., Jones, B. J., & Kooijman, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16374
Avances farmacológicos en la lucha contra la obesidad
Portero, P. C. (2025) · Panorama actual del medicamento · doi:10.63105/49.481.1
Nouveaux médicaments de l’obésité : quelle pertinence ?
Bringer, J. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.008
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Glucagon-like-peptide-1 receptor agonists in diabetes mellitus
Abu, M. S. P., Pradeep, G. K., Baby, B., Premjith, S., Venugopal, A., & Joy, S. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00006-3
Chigurupati, M. (2025) · Journal of medical and dental science research. · doi:10.35629/076x-12039499
Pediatric Obesity Pharmacotherapy
Speakman, A., Ali-Geiger, F., & Mouzaki, M. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.05.001
Pharmacotherapy of Energy Metabolism in Obesity
(2025) · Frontiers Media SA eBooks · doi:10.3389/978-2-8325-6300-7
soler, J. J. G. (2025) · Galicia Clínica · doi:10.22546/86/1/1447
Traitements médicamenteux par agonistes des récepteurs au GLP1 et obésité de l’adulte
Carette, C., Phan, A., & Czernichow, S. (2025) · Soins · doi:10.1016/j.soin.2025.05.020
Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
Hollstein, T. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2606-7020
Comparison of Anti-Obesity Effects of Ginger Extract Alone and Mixed with Long Pepper Extract
Song, G., Han, H., Jin, H., Kim, J., Kim, H., Seo, Y.-S., Song, H., & Lee, B. (2025) · Biomedicines · doi:10.3390/biomedicines13092077
“In addition, GLP-1 concentrations were also elevated in the GE group, which may have contributed to the observed improvements in glucose homeostasis by enhancing insulin secretion [42,43].”
Emerging Therapeutic Agents for Obesity and Future Perspectives
Otoda, T. (2025) · Journal of Nihon University Medical Association · doi:10.4264/numa.84.4_185
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Tratamiento de la obesidad desde una perspectiva cardiovascular
Giménez, S., Arrupe, M. F., Renna, N. F., Stival, J. L. R., Cobo, A. L., Forte, E. H., Silveyra, J., Terns, P. P., Alcalá, G., Piskorz, D. L., et al. (2023) · Revista de la Federación Argentina de Cardiología · doi:10.63600/xz3tg433 · Cited by 2
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Hernández, A. R., Araujo, J. E. G., Castillo, J. F. D., Martínez, M. E. A., Cohen, N. E. Z., Navarro, A. F. U., Chavez, M. A. N., & Morales, A. L. L. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/tg610p62
La chirurgia bariatrica è ancora un’opzione di prima scelta nel trattamento dell’obesità?
Capoccia, D., & Milani, I. (2025) · il Diabete · doi:10.30682/ildia2503e
Shao, Y., Ju, F., Qian, J., Tang, L., & Chen, S. (2025) · Adipocyte · doi:10.1080/21623945.2025.2583542 · Cited by 1
“Lifestyle modifications suffer from poor long-term adherence; pharmacological agents are constrained by adverse effects and contraindications; and bariatric surgery, while most effective, is restricted by its invasiveness, cost, and limited eligibility [28–30].”
EndoCompass Project: Research Roadmap for Diabetes, Obesity, and Metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000549194 · Cited by 1
“…for an obesity indication, showing a mean weight loss of −17.4% [61] Orforglipron is an oral, partial GLP-1 receptor agonist, which is biased towards G-protein activation over β-arrestin recruitment at the GLP-1 receptor, and is undergoing phase 3 trials for the treatment of obesity treatment [62].”
InfluentialCentral monoaminergic pathways in appetite regulation
Aklan, İ. (2023) · Iowa Research Online (The University of Iowa) · doi:10.25820/etd.006890
López, G. P. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107122 · Cited by 2
Moiz, A. (2025) · eScholarship@McGill (McGill) · doi:10.82308/2683
GLP-1 Receptor Agonist Impact on Fracture Risk In Patients with Obesity
Chelton, A., Lawson, E., Boghara, S., & Jenney, F. E. (2025) · Journal of the American Osteopathic Academy of Orthopedics · doi:10.70709/ellc5ccpa22
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
“This medication is taken as a once daily oral medication and requires no dietary or fluid restrictions [56].”
Anti-obesity drugs: comprehensive review and emerging therapies
Marne, P., Patil, S. D., Vora, A., MohdSiddique, M. U., Gadkari, Y. U., & Kurkute, P. (2026) · Endocrine · doi:10.1007/s12020-025-04528-w · Cited by 1
“Compared to peptide GLP-1 receptor agonists, orforglipron may provide less receptor desensitization due to its strong pharmacologic profile, which primarily affects cyclic AMP (cAMP) signalling rather than β-arrestin recruitment [ 165].”
Influentialmerging Advances in Oral and Injectable Anti-Obesity Pharmacotherapies: A Review of Current Evidence
Madsbad, S. (2025) · Medical Research Archives · doi:10.18103/mra.v14i1.7208
Managing Obesity in Heart Failure Patients: Current Evidence and Strategies
Sharma, S., Giri, G. K., Desai, A., Ruiz, J., Gomez, V., & GOSWAMI, R. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.016
Treatment of obesity: New drugs
Berti, S., Garelli, S., & Pagotto, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00330-7
Medikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., & Dovč, K. (2026) · DiRROS repository (University of Maribor)
Is pharmacotherapy ready to redefine the state of the art in obstructive sleep apnea care?
Johnston, E. K., Bird, E. M., Malhotra, A., & Harding, C. D. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2634201
“Small molecule alternatives such as orforglipron may also provide oral options [6].”
王, 钰. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.163787
TRENDS IN OBESITY TREATMENT: A REVIEW OF THE LITERATURE FROM THE LAST SIX YEARS
Sobiński, A., Sadowska, A., Welkier, A., Miśkiewicz, J., Dudek, A., Pietrusińska, P., Moder, J., Dziewierz, A., Kwaśniewska, P., & Śliwa-Tytko, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4326
Retatrutide in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2642415
“Advances in pharmacology might allow a less frequent administration, similar to other currently available agents, but with more pronounced effects [65, 66].”
Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes
Neeland, I. J., & Baskin, R. L. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00004-5
Moiz, A., Reynier, P., Tsoukas, M. A., Yu, O. H., Peters, T. M., Eisenberg, M. J., & Filion, K. B. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03153-6
“Novel agents, including the triple-agonist retatrutide (GLP-1/GIP/glucagon RA) and oral agonist orforglipron (GLP-1 RA), have also shown promising efficacy in early-phase trials [12, 13].”
Xu, H., Hu, W., Ln, Z., Tu, W., Shen, L., Zhang, G., ZHONG, L., Liu, J., XU, J., & Li, X. (2026) · Obesity · doi:10.1002/oby.70160
“Other oral nonpeptide GLP-1RAs, such as danuglipron and orforglipron, have demonstrated reductions in body weight of up to 7.17 and 13.3 kg at weeks 12 and 26, respectively, in individuals with obesity in phase 2 studies [14, 18].”
InfluentialCurrent trends in pharmacotherapy of overweight and obesity
Ürgeová, A., & Kozárová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.099
Incretin polyagonists as an alternative to bariatric surgery to manage obesity
Manoj, R. J., Fernandez, C. J., Nair, S., & Pappachan, J. M. (2026) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v17.i1.118132
“…vomiting, diarrhea) remain the most frequent cause of treatment discontinuation - reported in about 10%-17% of patients in oral GLP-1 RA studies and up to 7% for injectable polyagonists - yet these events are typically dose-related and often transient, more common during dose escalation[27,28].”
VALENZA, M. (2026) · Electronic Theses and Dissertations Repository (University of Pisa)
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
“Indeed, in a sub-analysis of previously described Phase 2 trials [84,85], orforglipron treatment in patients with T2D and/or over-weight or obesity was associated with a significant reduction in BP, triglycerides, LDL-C, ApoB, ApoC3, and hsCRP [90].”
InfluentialPancreatic islet transplantation in patients with diabetes and a kidney transplant
Maanaoui, M. (2023) · theses.fr (ABES) · doi:10.70675/61568379z2dd9z4639z8fe3z5d212aa95b82
Gęborys, A., Wojcieszak, M., Dąbrowska, J., Miazga, D., Maziarczyk, A., Lambach, J., Kutnik, K., Kania, J., Woźnica, W., & Białogłowski, M. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.90.69970
“The OASIS 1 and PIONEER PLUS studies show that oral semaglutide (up to 50 mg) has similar efficacy for weight loss as the injectable formulations [30, 31, 32].”
Yau, K. Y. T. (2025) · TSpace (University of Toronto)
The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
Sun, L. L., Liu, H. F., Zhang, X., Zuo, F., Kong, Y., Feng, J., & Nian, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04534-2
Mihălțan, F.-D., Borcea, C.-I., & Constantin, A. A. (2026) · Life · doi:10.3390/life16050802
“In addition, the potential use of emerging agents, such as oral nonpeptide GLP-1 receptor agonists (e.g., orforglipron), to maintain weight loss following tirzepatide therapy warrants investigation [95,96].”
Chen, Z., Yang, Q., Liu, J. S., Zhao, H., Ying, H., Liu, H., Huang, L., Lin, H. Y., Wang, S., Li, M., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04888-8
“For instance, recent studies hypothesize that semaglutide may induce cardiac atrophy in experimental models [74], and clinical usage has been associated with elevated heart rates [71].”
Orforglipron as a Small-Molecule GLP-1 Receptor Agonist: A New Era of Incretin-Based Oral Therapy?
Blecharczyk, M., Jakimowicz, A., Kamińska, Z. Z., Malcher, A., Mrozek, M., Pacanowska-Trawnicka, M., Zielinska, A., & Zydlewski, I. (2026) · Quality in Sport · doi:10.12775/qs.2026.56.72512
MIRI, M. L. B., Pereira, M. V. I. L., Barbalho, E. L., Barbosa, M. P., do Carmo, N. F., & Becchi, V. (2026) · Arquivos Catarinenses de Medicina · doi:10.63845/27vewf30
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review
Fuentes‐Mendoza, J. M., Concepción‐Zavaleta, M. J., Dueñas, L. G. D., Jara-Pianto, J. M. J., Sierra-Martel, J. A., Medina-Angulo, C. A., Flores, H. M. V., Mendoza-Godoy, J. J., Zavaleta‐Gutiérrez, F. E., & Paz‐Ibarra, J. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.118730
Castro-Gamboa, J. A., Mora-Jiménez, J., Arguedas‐Chacón, S., & Zavaleta‐Monestel, E. (2026) · Cureus · doi:10.7759/cureus.110178
“…food-related administration constraints as an oral nonpeptide small-molecule agonist, but the benchmark established by injectable semaglutide underscores the need to avoid framing oral convenience as a substitute for direct evidence of equal or greater efficacy across the full class [16,17,41].”
InfluentialZarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“In parallel, non-peptide oral agents such as orforglipron have shown promising glycemic and weight-related effects in phase 2 studies [300, 301].”
Bergia, R. E., Brown, A. W., Braun, M. M., & Messina, M. J. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100689 · Cited by 1
“…pressures, expanding EOM pipelines poised to commoditize older effective variants [40], more acceptable modalities supporting easier administration [41], and other potential evolutions (e.g., Medicare coverage) — make it plausible that a substantially larger share of adults with overweight and…”
English, K. J., & Kumar, K. A. (2026) · World Journal of Methodology · doi:10.5662/wjm.121475
Santulli, G. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00321-4
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Mohamed, M. R., Abdallfatah, A., Elsekhary, A., El‐Nemr, A. F., Eladawi, S., Maihoub, O., Abdulhay, H., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70275
Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling
Deng, Y., Zr, G., Yu, L., Zhang, J. W., Qian, J., Wang, J., Chen, X., Xu, Z., Wang, D., & Kong, C. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118294
Garvey, W. T., Rosenstock, J., Bays, H. E., Denham, D. S., Kohli, A., Haines, M., Jones, C., Kwan, E., CASTELLOE, E. N., Marmon, T., et al. (2026) · Obesity · doi:10.1002/oby.70271
Self-citationVanderheyden, G., & Haubrick, K. (2026) · Journal of Food Studies · doi:10.5296/jfs.v15i1.23736
Oral Agents Used to Treat Type 2 Diabetes and Obesity
Liddle, J., Ratkova, E. L., Bonito, C. A., Rhodes, C. J., & Will, S. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch5
Laffin, L. J., Schlaich, M. P., Hall, M. E., Xie, C. C., Rao, G. S., Rettiganti, M., Dennehy, E. B., & Linetzky, B. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101783
“This was estimated based on SBP data obtained in previous clinical trials investigating GLP-1/GIP therapies [28,33].”
Wang, R., Liu, Q., Lu, C., Chen, K., Liu, S., Guo, L., Guo, Z., Liu, Y., & Zhang, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119206
Pocock, L. (2026) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2026.241809
Zou, G., Yang, C., Wu, Q., Guo, M., & Liu, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02264-3
Kenkishvili, A. S., Arutyunyan, M. E., & Maksimov, M. L. (2026) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2607-07
Retatrutide: prospects and potential risks in oncology and ophthalmology
Kenkishvili, A. S., Arutyunyan, M. E., & Maksimov, М. L. (2026) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2607-03
Corona, G., Sparano, C., Romeo, M., Sedigh, O., Bettocchi, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.260045
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
“Emerging therapies include oral semaglutide and non-peptide incretin agonists such as orforglipron, which may further expand therapeutic options (Wharton et al., 2023; Wharton et al., 2025b).”
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“Approved in April 2026 [239].”
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
GLP-1 Receptor-Targeted Nanomedicine: Emerging Pharmaceutical Strategies for Diabetes Therapy
Pandey, A., Priya, M., Kumar, G., Gupta, K. K., Raj, S., & Mandal, R. K. (2026) · International Journal of Biomedical Investigation · doi:10.31531/2581-4745.1000181
ภาวะอ้วนและโรคไต: กลไกและการรักษาใหม่
ศุภศิลป์, ฐ., & สถิระพจน์, บ. (2026) · Journal of the Nephrology Society of Thailand · doi:10.63555/jnst.2026.289162
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.013
RetractedRecent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review
Puspitasari, I. M., Putra, D. S., Deliyana, A. N., Adiputri, N. I., Octovia, L. I., Paramita, S. A., & Sinuraya, R. K. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s626279
“39 Once-daily oral orforglipron produced dose-dependent weight loss ranging from 9.4% to 14.7% after 36 weeks compared with 2.3% with placebo, 39 while maintaining a safety profile generally comparable to injectable GLP-1 RA.”
InfluentialThe promise of biased ligands in therapeutics
Eiger, D. S., Smith, J. S., & Rajagopal, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100160
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.68.79
Shah, J., Ceron, E. L., Payan‐Schober, F., Hechanova, L. A., Clegg, D. J., & Palmer, B. F. (2026) · American Journal of Nephrology · doi:10.1159/ajn/ablag011
ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Wielogórska, A., Stasiak, O., Kowalik, F., & Deczkowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5972
Hu, J., Zhang, Y., Wang, M., Zhang, B., Zhang, B., Ke, C., Tang, C., Xia, J., Zhao, Q., Gao, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00175
Structural Overview of GLP-1 Analogs
van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037
Zhang, T., Luo, X., Chen, C., Zhang, Y., Xu, B., He, Z., & Zhou, J. (2026) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346261487722
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
“Another two (Rosenstock et al., 2026) and (Wharton et al., 2023) exhibited unclear risk in the second and third domains, respectively.”
InfluentialTamrakar, S., Pe, L. S., Panmanee, J., Yang, J., & Mukda, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119946
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment
Wietholter, J. P., & Terpening, C. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261486055
Practical use of GLP-1-based medications in obesity clinics
Jethwani, P. D., Hallock, R., & Griebeler, M. L. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.011
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
“Their place in cardiometabolic care will depend not only on weight reduction but also on cardiovascular and kidney outcomes, long-term safety, treatment persistence, and access [ 78 , 79 ].”
Gupta, K., Zeinali, M., Altschul, D., Agarwal, V. J., & Karsy, M. J. (2026) · Pituitary · doi:10.1007/s11102-026-01760-z
“Bariatric surgery is considered for CP patients with severe obesity resistant to conventional treatments [7, 29]”
Novel Pharmacological Advancements in Obesity Management. The era of incretins and their analogs
Triantis, C., & Theodosis‐Nobelos, P. (2026) · Pharmakeftiki
Evans, J. M. (2025) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective
Ahmad, I., Azmi, S., Albabtain, M. A., Mustafa, M., Kunnathodi, F., Riyasdeen, A., AlWhaiby, B. R., Alharbi, E. M., Arafat, A. A., & Alotaibi, H. F. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101281
“Its small-molecule scaffold permits oral administration without an empty-stomach requirement, while gastrointestinal adverse effects and gradual dose escalation remain consistent with on-target GLP-1R pharmacology [10,77–79].”
Gao, L., & Li, S. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.102132
Yacaman, G. J. P., López, A. M. J., Cordova, P. R., Cuenca, S. E. A., López, S. M., Lladó, A. I. C., Quintero, D. O. B., Bárcena, E. D. C., Mottú, R. A. Z., Flores, V. Z., et al. (2026) · Cureus · doi:10.7759/cureus.117774
Chen, Z., Zhou, Y., Li, G., MUTHANNA, A., d’Arqom, A., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02110-3
“Mild-to-moderate gastrointestinal adverse events were most common (10%-17% discontinuation rate) [164].”
Obesity: oral therapy for those afraid of needles
Vignera, S. L., & Condorelli, R. A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749645
Antidiabetic medications in the pipeline
Efstathiadou, Z. A., Gogakos, A. I., Divaris, E., Kostopoulos, G., & Makri, E. (2026) · HORMONES · doi:10.1007/s42000-026-00780-5
Metadata
- Authors
- Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., & Konig, M.
- Affiliations
- Eli Lilly (United States) (US)
- From McMaster University, York University, and Wharton Weight Management Clinic — all in Toronto (S.W.); Texas Diabetes and Endocrinology, Austin (T.B.), and Velocity Clinical Research at Medical City, Dallas (J.R.) — both in Texas; Alliance for Multispecialty Research, Norman, OK (L.C.); and Eli Lilly, Indianapolis (S.R., R.L., X.M., K.J.M., A.H., D.R., E.P., C.K., M.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-07
- Volume
- 389
- Issue
- 10
- Pages
- 877-888
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4381716537
- Semantic Scholar
- db8284957df7f480bc8b5957f73388bfd42590cf
- Cited by
- 478
- References
- 19
- Citations by year
- 2026: 125 · 2025: 175 · 2024: 133 · 2023: 45
- FWCI
- 74.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- orforglipron, GLP-1 receptor agonists, obesity, weight loss, cardiometabolic risk, gastrointestinal adverse effects, dose escalation, overweight adults, weight change, drug safety and efficacy, weight-related comorbidities, dose-response relationship, dose-limiting adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.